[How does the landscape change in lysosomal storage disease].
Parini
R
R
Resp.Centro Fondazione Mariani per le Malattie Metaboliche, Clinica Pediatrica, Università Milano Bicocca, Ospedale S. Gerardo dei Tintori, Monza. rossella.parini@pediatriamonza.it
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000818:Animals; D002648:Child; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004195:Disease Models, Animal; D000795:Fabry Disease / Q000175:diagnosis / Q000188:drug therapy; D005776:Gaucher Disease / Q000175:diagnosis / Q000188:drug therapy; D006009:Glycogen Storage Disease Type II / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007223:Infant; D016464:Lysosomal Storage Diseases / Q000175:diagnosis / Q000188:drug therapy; D051379:Mice; D018345:Mice, Knockout; D008059:Mucopolysaccharidosis I / Q000175:diagnosis / Q000188:drug therapy; D009085:Mucopolysaccharidosis IV / Q000175:diagnosis / Q000188:drug therapy; D009542:Niemann-Pick Diseases / Q000175:diagnosis / Q000188:drug therapy; D011788:Quality of Life; D016896:Treatment Outcome